A PROSPECTIVE RANDOMIZED TRIAL OF ALEMTUZUMAB VERSUS RABBIT ANTI-THYMOCYTE GLOBULIN INDUCTION IN KIDNEY AND PANCREAS TRANSPLANTATION: MINIMUM 6 MONTHS FOLLOW-UP: 796